Newsroom

FOR RELEASE FRIDAY, MAY 19, 2006

ROCHESTER, N.Y. - Bausch & Lomb (NYSE: BOL) today announced that it has further extended the consent deadline in connection with its previously announced offer to purchase and consent solicitation with respect to its 7.125% debentures due 2028. 

The new consent deadline is 5:00 p.m., New York City time, on Wednesday, May 24, 2006. Holders who validly tender their 2028 debentures on or prior to the consent deadline will be eligible to receive the total consideration with respect to the debentures, which will be $1,000 per $1,000 principal amount thereof.  Holders validly tendering debentures after May 24, 2006, but on or before June 2, 2006, will receive the par value less $1.00 per $1,000 principal amount of the debentures.  A valid tender of debentures pursuant to the tender offers will also constitute a valid delivery of consent with respect to such debentures.

The extension of the consent deadline applies to the 7.125% debentures only.  The Company has received requisite consents with respect to the other issuances of notes and convertible notes included in the original tender offer and consent solicitation commenced on May 5, 2006.

---

Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world.  Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products.  The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world.  Founded in 1853, the Company is headquartered in Rochester, New York.  Bausch & Lomb's 2004 revenues were $2.2 billion; it employs approximately 12,400 people worldwide and its products are available in more than 100 countries.  More information about the Company can be found on the Bausch & Lomb Web site at www.bausch.com . Copyright Bausch & Lomb Incorporated.

® / ^TM denote trademarks of Bausch & Lomb Incorporated.

Increase Type Size

Decrease Type Size